Home Economy Regeneron receives $450M federal contract for its potential coronavirus cocktail

Regeneron receives $450M federal contract for its potential coronavirus cocktail

SHARE

Regeneron Pharmaceuticals has received a $450 million contract from the federal government to manufacture and supply REGN-COV2, its investigational treatment of COVID-19. The double antibody cocktail is currently in two phase 2/3 clinical trials and in a phase three trial for the prevention of COVID-19 infection.  According to a July 7 statement by the U.S. Department…

This content is for Westfair Online members only. Please to view this content. Become a member by Registering Here.
Print Friendly, PDF & Email